title: Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
abstract: BACKGROUND
  Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative neoplasms that increase the risk of arterial and venous thrombosis, as well as bleeding. In addition to the different therapeutic strategies available, an antiplatelet drug is often used to reduce thrombotic risk.
  
  
  OBJECTIVE
  To quantify the benefit and harm of antiplatelet drugs for long-term primary and secondary prophylaxis of arterial and venous thrombotic events in patients with polycythaemia vera or essential thrombocythaemia.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library (Issue 1 2012), MEDLINE (1966 to 2012), and EMBASE (1980 to 2012), as well as online registers of ongoing trials and conference proceedings. The date of the last search was October 2012.
  
  
  METHODS
  We included all randomised controlled trials (RCTs) comparing long-term (>6 months) use of an antiplatelet drug versus placebo or no treatment in participants with polycythaemia vera or essential thrombocythaemia, as diagnosed by established international criteria, with data for at least one of the selected outcomes.
  
  
  METHODS
  Using a pre-defined extraction form, two review authors independently screened results, extracted data, and assessed quality. We planned to analyse the following outcomes: mortality from arterial and venous thrombotic events (primary efficacy outcome), mortality from bleeding episodes (primary safety outcome), fatal and non-fatal arterial thrombotic events, fatal and non-fatal venous thrombotic events, micro-circulation events, transient neurological and ocular manifestations, major and minor bleeding episodes, and all-cause mortality and any adverse events. We based quantitative analysis of outcome data on an intention-to-treat principle. We used the pooled odds ratio (OR) with 95% confidence interval (CI) with a fixed-effect model (Mantel-Haenszel) to estimate the overall treatment effect.
  
  
  RESULTS
  We identified no new studies from the updated searches. We included in this review two RCTs for a total of 630 participants. Both RCTs included participants with an established diagnosis of polycythaemia vera and with no clear indication or contraindication to aspirin therapy. We judged both studies to be of moderate quality. Published data from both studies were insufficient for a time-to-event data analysis and for some of the primary and secondary outcomes that we planned. The use of low-dose aspirin, compared with placebo, was associated with a lower risk of fatal thrombotic events (although this benefit was not statistically significant (OR 0.20, 95% CI 0.03 to 1.14; P = 0.07). No data on mortality from bleeding episodes were available. A non-significant benefit of aspirin was shown for all-cause mortality (OR 0.46, 95% CI 0.21 to 1.01; P = 0.05). No increase in the risk of major bleeding was reported in participants taking aspirin compared with those given placebo (OR 0.99, 95% CI 0.23 to 4.36; P = 0.99), and a non-significant increase with aspirin treatment was shown for minor bleeding (OR 1.85, 95% CI 0.90 to 3.79; P = 0.09). No published studies have reported findings in participants with essential thrombocythaemia or in the study of other antiplatelet drugs.
  
  
  CONCLUSIONS
  For patients with polycythaemia vera who have no clear indication or contraindication to aspirin therapy, available evidence suggests that the use of low-dose aspirin, when compared with no treatment, is associated with a statistically non-significant reduction in the risk of fatal thrombotic events and all-cause mortality, without an increased risk of major bleeding.
authors: Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and ExperimentalMedicine,School of Medicine, University of Insubria, Varese, Italy. alexsquizzo@libero.it
authors: Alessandro
authors: A
authors: Squizzato
authors: Erica
authors: E
authors: Romualdi
authors: Francesco
authors: F
authors: Passamonti
authors: Saskia
authors: S
authors: Middeldorp
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D013920:Thrombocythemia, Essential / Q000188:drug therapy* / Q000401:mortality; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
references: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006503
references: 18425953
references: Br J Haematol. 1997 May;97(2):453-6
references: 9163613
references: N Engl J Med. 1995 Apr 27;332(17):1132-6
references: 7700286
references: Blood. 2005 Apr 1;105(7):2664-70
references: 15585653
references: Chest. 2012 Feb;141(2 Suppl):e89S-e119S
references: 22315278
references: N Engl J Med. 2005 Jul 7;353(1):33-45
references: 16000354
references: Am J Hematol. 1994 Oct;47(2):89-93
references: 8092146
references: Semin Hematol. 1986 Jul;23(3):172-6
references: 3749927
references: Acta Haematol. 1991;85(3):113-8
references: 2042443
references: J Clin Epidemiol. 2009 Oct;62(10):1006-12
references: 19631508
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Ann Intern Med. 1995 Nov 1;123(9):656-64
references: 7574220
references: Blood. 1992 Oct 15;80(8):1965-71
references: 1327286
references: Blood. 2002 Oct 1;100(7):2292-302
references: 12239137
references: Semin Thromb Hemost. 1997;23(5):473-8
references: 9387206
references: Blood. 2010 Aug 26;116(8):1205-10; quiz 1387
references: 20508163
references: Am J Epidemiol. 1987 Aug;126(2):161-9
references: 3300279
references: BMJ. 2006 Sep 16;333(7568):597-600
references: 16974018
references: N Engl J Med. 2004 Jan 8;350(2):114-24
references: 14711910
references: Am J Hematol. 1999 May;61(1):10-5
references: 10331505
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Thromb Haemost. 1995 Nov;74(5):1225-30
references: 8607099
references: Hematology Am Soc Hematol Educ Program. 2005;:201-8
references: 16304381
references: BMJ. 2002 Jan 12;324(7329):71-86
references: 11786451
references: J Clin Oncol. 2005 Apr 1;23(10):2224-32
references: 15710945
references: Am J Med. 2004 Nov 15;117(10):755-61
references: 15541325
references: Curr Opin Hematol. 2011 Mar;18(2):105-10
references: 21245760
references: Stat Med. 1998 Dec 30;17(24):2815-34
references: 9921604
references: J Clin Oncol. 1990 Mar;8(3):556-62
references: 2307991